CoChat
Cited by 160

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma

Open access
HEPAVAC Consortium, Löffler, Markus W., Mohr, Christopher, Bichmann, Leon, Freudenmann, Lena Katharina, Walzer, Mathias, Schroeder, Christopher M., Trautwein, Nico, Hilke, Franz J., Zinser, Raphael S., Mühlenbruch, Lena, Kowalewski, Daniel J., Schuster, Heiko, Sturm, Marc, Matthes, Jakob, Riess, Olaf, Czemmel, Stefan, Nahnsen, Sven, Königsrainer, Ingmar, Thiel, Karolin, Nadalin, Silvio, Beckert, Stefan, Bösmüller, Hans, Fend, Falko, Velic, Ana, Maček, Boris, Haen, Sebastian P., Buonaguro, Luigi, Kohlbacher, Oliver, Stevanović, Stefan, Königsrainer, Alfred, Rammensee, Hans-Georg · 2019 · Genome Medicine

Abstract

BACKGROUND: Although mutated HLA ligands are considered ideal cancer-specific immunotherapy targets, evidence for their presentation is lacking in hepatocellular carcinomas (HCCs). Employing a unique multi-omics approach comprising a neoepitope identification pipeline, we assessed exome-derived mutations naturally presented as HLA class I ligands in HCCs. METHODS: In-depth multi-omics analyses included whole exome and transcriptome sequencing to define individual patient-specific search spaces of neoepitope candidates. Evidence for the natural presentation of mutated HLA ligands was investigated through an in silico pipeline integrating proteome and HLA ligandome profiling data. RESULTS: The approach was successfully validated in a state-of-the-art dataset from malignant melanoma, and despite multi-omics evidence for somatic mutations, mutated naturally presented HLA ligands remained elusive in HCCs. An analysis of extensive cancer datasets confirmed fundamental differences of tumor mutational burden in HCC and malignant melanoma, challenging the notion that exome-derived mutations contribute relevantly to the expectable neoepitope pool in malignancies with only few mutations. CONCLUSIONS: This study suggests that exome-derived mutated HLA ligands appear to be rarely presented in HCCs, inter alia resulting from a low mutational burden as compared to other malignancies such as malignant melanoma. Our results therefore demand widening the target scope for personalized immunotherapy beyond this limited range of mutated neoepitopes, particularly for malignancies with similar or lower mutational burden.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-019-0636-8

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 160

Metadata

Authors
HEPAVAC Consortium, Löffler, M. W., Mohr, C., Bichmann, L., Freudenmann, L. K., Walzer, M., Schroeder, C. M., Trautwein, N., Hilke, F. J., Zinser, R. S., Mühlenbruch, L., Kowalewski, D. J., Schuster, H., Sturm, M., Matthes, J., Riess, O., Czemmel, S., Nahnsen, S., Königsrainer, I., Thiel, K., Nadalin, S., Beckert, S., Bösmüller, H., Fend, F., Velic, A., Maček, B., Haen, S. P., Buonaguro, L., Kohlbacher, O., Stevanović, S., Königsrainer, A., & Rammensee, H.-G.
Venue
Genome Medicine
Published
2019-04-30
Volume
11
Issue
1
Pages
28-28
ISSN
1756-994X (ISSN-L)
OpenAlex
W2945606195
Cited by
160
References
27
FWCI
9.34
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. https://app.cochat.ai/papers/10.1186/s13073-019-0636-8
The paper
HEPAVAC Consortium, Löffler, M. W., Mohr, C., Bichmann, L., Freudenmann, L. K., Walzer, M., Schroeder, C. M., Trautwein, N., Hilke, F. J., Zinser, R. S., Mühlenbruch, L., Kowalewski, D. J., Schuster, H., Sturm, M., Matthes, J., Riess, O., Czemmel, S., Nahnsen, S., Königsrainer, I., . . . Rammensee, H.-G. (2019). Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Medicine. https://doi.org/10.1186/s13073-019-0636-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.